Sexual Dysfunction in Male Patients After Initiating Treatment with Antidepressants.

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Epidemiology

Background:

• Sexual side effects are known adverse events associated with serotonergic antidepressants.
• Limited observational data exists comparing the risk of sexual dysfunction among specific antidepressant medications.

Purpose of the Study:

• To compare the risk of developing healthcare-recorded sexual dysfunction in male patients initiating treatment with citalopram, sertraline, venlafaxine, or mirtazapine.
• To provide comparative risk data for antidepressant-induced sexual dysfunction.

Main Methods:

• A new-user, active comparator cohort study was conducted using Danish national healthcare registers from 2001-2015.
• Included 170,580 new treatment episodes for citalopram, 67,721 for mirtazapine, 51,984 for sertraline, and 19,820 for venlafaxine in adult males.
• Analyses utilized incidence rates and propensity score-matched hazard ratios, with a 1-year follow-up and washout period.

Main Results:

• Venlafaxine was associated with the highest risk of sexual dysfunction compared to citalopram (HR 1.27).
• This risk was significantly higher for venlafaxine in patients with prior depression-related hospital visits (HR 1.93).
• Sertraline showed no significant difference in risk (HR 0.99), while mirtazapine indicated a potential lower risk than citalopram (HR 0.87).

Conclusions:

• The risk of antidepressant-associated sexual dysfunction differs among commonly prescribed medications.
• Clinicians should counsel patients on potential sexual side effects, especially when choosing between multiple antidepressant options.